Dipeptidyl peptidase 4 (DPP-4) inhibitors

Alogliptin and Metformin Hydrochloride

Approved 27 Nov 2019OralTablet

The FDA lists this product in 2 strengths and forms.

Official labelAsk Osler about it

Composition

Active ingredients: ALOGLIPTIN AND METFORMIN HYDROCHLORIDE 12.5MG/500MG

Strengths and forms

The FDA lists each strength of a product separately; these pages share one label.

ALOGLIPTIN AND METFORMIN HYDROCHLORIDE 12.5MG/1000MG · TabletANDA210212-002 · Tentative approval
ALOGLIPTIN AND METFORMIN HYDROCHLORIDE 12.5MG/500MG · TabletThis page

Official product information

Drugs@FDA lists the approved labels, letters and reviews for application ANDA210212.

Open Drugs@FDA

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Brand name: Alogliptin and Metformin Hydrochloride
Drug class: Dipeptidyl peptidase 4 (DPP-4) inhibitors, Combinations of oral blood glucose lowering drugs, Biguanides
Group: Diabetes medicines
Route: Oral
Dosage form: Tablet
Applicant: MSN Laboratories Private LTD
Status: Tentative approval
FDA approval: 27 Nov 2019
Application: ANDA210212-001
RxCUI: 1368384